Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.

Detailed Description
-----------------
There is currently no strong prognostic factor in pancreatic cancer. K-ras is the most commonly mutated gene in pancreatic cancer, with a mutation rate of 75% to 95%. These high mutation rates are expected to be useful for diagnosis and prognostic factors in future. Currently, K-ras mutation tests are often performed in tissues, and there are various limitations, in particular, limited obtaining of sufficient tissues. In this regard, analyzing the prognosis of pancreatic cancer through non-invasive blood testing has significant advantages. And Prognosis analysis through blood tests can be done through blood circulating tumor DNA. The relationship between prognosis and blood circulating tumor DNA has already been studied in other cancers such as colorectal cancer, and there have been several studies in pancreatic cancer. However, there are not many research results yet, and there are cases in which the results differ from study to study. Therefore, the purpose of this study is to compare the overall survival of patients with pancreatic cancer diagnosed by EUS-FNA according to the presence and amount of blood circulating tumor DNA with K-ras mutation.

Official Title
-----------------
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with pancreatic cancer through EUS-FNA. Exclusion Criteria: Severe mental illness Severe co-morbidity (ESRD, Advanced COPD, severe Heart failure, poorly controlled blood sugar) Pregnancy Patients who have received chemotherapy Coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival rate | Comparison of overall survival rates between patients with and without blood-circulating tumor DNA | 48 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival rate according to the amount of blood circulating tumor DNA | Overall survival rate according to the amount of blood circulating tumor DNA | 48mo | 
| K-ras mutation | The concordance rate of K-ras mutation in EUS-FNA specimen and K-ras mutation in blood circulating tumor DNA | 48 months | 
| Overall survival rate (EUS-FNA) | Overall survival rate with or without K-ras mutation of EUS-FNA specimen | 48 months | 
| Overall survival rate (K-ras mutation type, circulating tumor DNA) | Overall survival rate according to K-ras mutation type in blood circulating tumor DNA | 48 months | 
| Overall survival rate (K-ras mutation type, EUS-FNA) | Overall survival rate according to K-ras mutation type in EUS-FNA specimen | 48 months |